# Ipamorelin FAQ: Direct Answers on the Stack, Effects, and Evidence

> Ipamorelin questions answered directly and cited: how the CJC-1295 stack works, whether it makes you hungry, the half-life, the failed trial, and why it was never approved.

Twenty-two real questions, each answered in a few cited sentences — no throat-clearing.

## What does CJC-1295 and ipamorelin do?

Together they raise growth hormone through two receptors at once: CJC-1295 drives the GHRH pathway while ipamorelin fires a selective ghrelin-receptor pulse. A 2026 orthopaedic narrative review found the pair improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss mouse model, but stressed the evidence is limited to animal studies [17]. The combination has no controlled human outcome trial.

## How much CJC-1295 ipamorelin should I take?

There is no evidence-based dose. No controlled human trial has performed dose-finding for the combination, so any specific figure online is community convention, not a studied amount [13][17]. Ipamorelin's only human doses were given by IV in research settings [2][3], and this site does not provide a self-administration dose, volume, or schedule for the stack.

## Does CJC-1295 ipamorelin work?

The mechanism raises growth hormone in the short term, and class-level human data support GHRP + GHRH synergy [8][13]. But no controlled human outcome trial of this specific combination has proven a wellness benefit. A 2024 review found a muscle-tension effect in mice while noting the evidence is animal-only [17]; a 2026 review flagged the absence of rigorous human trials and the potential for serious harm [18].

## Where to inject CJC-1295 ipamorelin?

Community protocols use subcutaneous injection, but these regimens have no peer-reviewed human basis and this site gives no administration instruction. The only human ipamorelin doses on record were intravenous, in a hospital research setting [2][3]. Subcutaneous self-injection — the dominant real-world route — has never been characterized for safety or pharmacokinetics in humans.

## Can you take CJC-1295 ipamorelin and sermorelin together?

There is no controlled trial of that three-way combination, so its safety and effect are uncharacterized. Mechanistically, sermorelin and CJC-1295 are both GHRH analogs — adding both would be largely redundant on the same receptor, while ipamorelin supplies the separate ghrelin-receptor pulse. This site does not recommend any combination; the class-level synergy data involve only paired GHRP + GHRH studies [7][8].

## Can you take tesamorelin and ipamorelin together?

No controlled trial has tested tesamorelin plus ipamorelin. Tesamorelin is an FDA-approved GHRH analog; ipamorelin is an unapproved ghrelin-receptor peptide [3]. Mechanistically they hit different receptors, so the pairing parallels the CJC-1295 stack, but no human study supports it and this site gives no dosing guidance for it. The class synergy evidence comes from other GHRP + GHRH pairs [8][9].

## What is ipamorelin?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) to release a growth-hormone pulse. Its 1998 founding study showed potent growth-hormone release (swine ED50 2.3 nmol/kg) with no rise in cortisol — the first selective growth-hormone secretagogue [1]. It is not an approved drug [3].

## What does ipamorelin do for you?

In studies, ipamorelin triggers a discrete pulse of growth hormone by acting on the ghrelin receptor, without raising cortisol or prolactin [1]. Preclinically it increased rat bone growth dose-dependently [4] and reduced chemotherapy-related weight loss in ferrets [5]. In humans, its only efficacy trial — for postoperative ileus — failed [3]. Community-reported effects (sleep, recovery) are anecdotal.

## What is ipamorelin peptide?

It is a five-amino-acid chain (a pentapeptide) engineered for protease resistance and receptor selectivity. Derived from GHRP-1, its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and it acts as a selective GHS-R1a (ghrelin receptor) agonist [1]. "Peptide" simply means a short protein-like chain; ipamorelin is among the most selective growth-hormone-secretagogue peptides characterized.

## What are the risks of ipamorelin?

The documented risks center on uncharacterized long-term safety: no Phase 3 trial, no long-term human database, and a class-level cardiotoxicity signal — a 28-day rat study of a related ghrelin-receptor agonist found dose-dependent myocardial degeneration [6]. Theoretical concerns include IGF-1-related tumor promotion and impaired glucose control [16]. The one human trial showed no specific safety signal in a 7-day window [3].

## Does ipamorelin reduce belly fat?

There is no human evidence that ipamorelin reduces belly fat. In a 2024 ferret study, intraperitoneal ipamorelin reduced cisplatin-induced weight *loss* by about 24% — a weight-protective effect, not fat loss [5]. In mice, it actually increased adiposity and leptin through a GH-independent mechanism [14]. Community reports of a leaner look over weeks are anecdotal and confounded by diet and training.

## What are the downsides of ipamorelin?

The central downside is that the human evidence is thin and partly negative: the only efficacy trial failed [3], and no long-term safety data exist. Community-reported downsides include post-injection flushing, tingling, water retention, increased hunger, and a fading response after a few months — all anecdotal. The class-level cardiac signal [6] and GH-axis cautions are the documented concerns.

## Why is ipamorelin being discontinued?

Ipamorelin was never a marketed drug to discontinue — its clinical development stopped after the Phase 2 ileus trial missed its primary endpoint (25.3 vs 32.6 hours, p=0.15) [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at the October 2024 PCAC meeting, restricting compounding-pharmacy access.

## Does ipamorelin increase IGF-1?

Not reliably in short studies. In the dose-dependent rat bone-growth study, ipamorelin raised bone growth with no measurable change in total IGF-1 [4], suggesting early effects are driven by the growth-hormone pulse itself rather than sustained IGF-1 elevation. Class-level data show that chronic GHRP + GHRH co-administration *can* sustain IGF-1 [7], but ipamorelin monotherapy does not consistently do so.

## How does CJC-1295 ipamorelin work?

The two peptides hit growth hormone through different receptors: CJC-1295 activates the GHRH receptor (cAMP pathway) for a sustained drive, while ipamorelin activates the ghrelin receptor (GHS-R1a, calcium pathway) for a discrete pulse [1]. Because the pathways are distinct, their effects can stack rather than overlap — the published rationale for the pairing [13]. The synergy is documented at the class level [8].

## How to reconstitute CJC-1295 ipamorelin 5mg?

As a general handling note: ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water for research handling, then kept refrigerated because peptides degrade with heat and freeze-thaw. This is a storage observation, not a dosing instruction — this site provides no milligram-to-milliliter math, injection volume, or preparation guidance for human use.

## How long does ipamorelin stay in your system?

Ipamorelin's terminal half-life in healthy human volunteers is approximately 2 hours after IV dosing, with the growth-hormone pulse peaking around 40 minutes [2]. With a ~2-hour half-life, the peptide itself clears within several hours. The downstream growth-hormone pulse it triggers is brief and discrete rather than sustained [2].

## Does ipamorelin make you hungry?

It can, because it acts on the ghrelin (hunger) receptor. Acute central ghrelin-receptor activation induced feeding in rats — a class-level appetite effect [15]. Community reports describe a hunger bump after injecting, generally milder than with GHRP-6 but still present for some. The selectivity that spares cortisol does not remove the appetite signal, which runs through the same receptor.

## Will I gain weight on ipamorelin?

There is no human data to answer this directly. In mice, ipamorelin increased body weight, fat-pad weight, and leptin through a GH-independent mechanism [14]. In a ferret cachexia model it protected against weight *loss* [5]. Community reports vary. Any weight change would be confounded by appetite effects [15], diet, and training; no controlled human study has measured it.

## Does ipamorelin increase appetite?

Mechanistically, yes — it is a ghrelin-receptor agonist, and ghrelin is the body's hunger hormone; class-level studies show central ghrelin-receptor activation induces feeding [15]. Reported appetite increase is described as milder than with GHRP-6 but real for some users (anecdotal). Mouse data also show GH-independent increases in adiposity and leptin alongside the appetite mechanism [14].

## What does ipamorelin peptide do?

It selectively triggers a growth-hormone pulse by activating the ghrelin receptor, without the cortisol or prolactin spillover of older peptides [1]. In animals it increased bone growth [4] and protected against chemotherapy weight loss [5]; in its one human efficacy trial it failed [3]. It is studied as the pulsatile half of growth-hormone peptide stacks [13].

## How long does it take for ipamorelin to work?

Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes after dosing in humans [2]. For the subjective effects people chase — sleep, recovery — community reports describe onset within one to two weeks, but these are anecdotal and unverified, with no controlled human trial measuring an onset time for any wellness outcome.

---

A trading-desk reading of the ipamorelin and combination-stack record — the selective GH pulse logged first as the one clean number, the CJC-1295 pairing read as class-level pharmacology rather than a tested product, and the failed human trial and missing long-term safety left openly unhedged; no clinic behind the console and nothing here dosed, stacked, prescribed, or sold.